UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/572,736	03/21/2006	Wael Mohamed Nabil Lotfy	SAI-004.01	6896
25181 FOLEY HOAG	7590 09/05/200 r, LLP	EXAMINER		
PATENT GROUP, WORLD TRADE CENTER WEST			STROUD, JONATHAN R	
	155 SEAPORT BLVD BOSTON, MA 02110		ART UNIT	PAPER NUMBER
			MAIL DATE	DELIVERY MODE
			09/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/572,736	LOTFY, WAEL MOHAMED NABIL		
Office Action Summary	Examiner	Art Unit		
	JONATHAN R. STROUD	3774		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	L. viely filed the mailing date of this communication.		
Status				
Responsive to communication(s) filed on <u>21 M</u> .      This action is <b>FINAL</b> . 2b) ☑ This 3) ☐ Since this application is in condition for allowar closed in accordance with the practice under Example 2.	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) 1,2 and 7-22 is/are pending in the app 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1,2 and 7-22 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.			
Application Papers				
9)☑ The specification is objected to by the Examine 10)☑ The drawing(s) filed on 21 March 2006 is/are: a Applicant may not request that any objection to the a Replacement drawing sheet(s) including the correct 11)☐ The oath or declaration is objected to by the Ex	a)  accepted or b)  objected to drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	ite		

Art Unit: 3774

#### **DETAILED ACTION**

## **Drawings**

1. The informal drawings are not of sufficient quality to permit examination.

Accordingly, replacement drawing sheets in compliance with 37 CFR 1.121(d)

are required in reply to this Office action. The replacement sheet(s) should be

labeled "Replacement Sheet" in the page header (as per 37 CFR 1.84(c)) so as

not to obstruct any portion of the drawing figures. If the changes are not accepted

by the examiner, the applicant will be notified and informed of any required

corrective action in the next Office action.

Failure to timely submit replacement drawing sheets will result in

ABANDONMENT of the application.

### Specification

2. The disclosure is objected to because of the following informalities: 1) the specification is arranged incorrectly, lacks double spacing, and is generally lacking in detail. 2) The abstract should be 150 words or less and comprise a brief description of the invention; as it stands, it is merely the first page of the PCT application of the same invention.

Appropriate correction is required.

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

Art Unit: 3774

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC.
- (f) BACKGROUND OF THE INVENTION.
  - (1) Field of the Invention.
  - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF THE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (I) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

#### Content of Specification

- (a) <u>Title of the Invention</u>: See 37 CFR 1.72(a) and MPEP § 606. The title of the invention should be placed at the top of the first page of the specification unless the title is provided in an application data sheet. The title of the invention should be brief but technically accurate and descriptive, preferably from two to seven words may not contain more than 500 characters.
- (b) <u>Cross-References to Related Applications</u>: See 37 CFR 1.78 and MPEP § 201.11.
- (c) <u>Statement Regarding Federally Sponsored Research and Development</u>: See MPEP § 310.

Application/Control Number: 10/572,736

Art Unit: 3774

(d) <u>The Names Of The Parties To A Joint Research Agreement</u>: See 37 CFR 1.71(g).

Page 4

- (e) Incorporation-By-Reference Of Material Submitted On a Compact Disc: The specification is required to include an incorporation-by-reference of electronic documents that are to become part of the permanent United States Patent and Trademark Office records in the file of a patent application. See 37 CFR 1.52(e) and MPEP § 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text were permitted as electronic documents on compact discs beginning on September 8, 2000.
- (f) <u>Background of the Invention</u>: See MPEP § 608.01(c). The specification should set forth the Background of the Invention in two parts:
  - (1) <u>Field of the Invention</u>: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled "Technical Field."
  - (2) Description of the Related Art including information disclosed under 37 CFR 1.97 and 37 CFR 1.98: A description of the related art known to the applicant and including, if applicable, references to specific related art and problems involved in the prior art which are solved by the applicant's invention. This item may also be titled "Background Art."
- (g) Brief Summary of the Invention: See MPEP § 608.01(d). A brief summary or general statement of the invention as set forth in 37 CFR 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention.
- (h) <u>Brief Description of the Several Views of the Drawing(s)</u>: See MPEP § 608.01(f). A reference to and brief description of the drawing(s) as set forth in 37 CFR 1.74.

Application/Control Number: 10/572,736

Art Unit: 3774

(i) Detailed Description of the Invention: See MPEP § 608.01(g). A description of the preferred embodiment(s) of the invention as required in 37 CFR 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication which adequately describes the subject matter.

Page 5

- (j) Claim or Claims: See 37 CFR 1.75 and MPEP § 608.01(m). The claim or claims must commence on separate sheet or electronic page (37 CFR 1.52(b)(3)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate subcombinations or related steps. See 37 CFR 1.75 and MPEP § 608.01(i)-(p).
- (k) Abstract of the Disclosure: See MPEP § 608.01(f). A brief narrative of the disclosure as a whole in a single paragraph of 150 words or less commencing on a separate sheet following the claims. In an international application which has entered the national stage (37 CFR 1.491(b)), the applicant need not submit an abstract commencing on a separate sheet if an abstract was published with the international application under PCT Article 21. The abstract that appears on the cover page of the pamphlet published by the International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the abstract that will be used by the USPTO. See MPEP § 1893.03(e).
- (I) <u>Sequence Listing.</u> See 37 CFR 1.821-1.825 and MPEP §§ 2421-2431. The requirement for a sequence listing applies to all sequences disclosed in a given application, whether the sequences are claimed or not. See MPEP § 2421.02.

Page 6

Art Unit: 3774

3. The spacing of the lines of the specification is such as to make reading difficult. New application papers with lines 1½ or double spaced on good quality paper are required.

### Claim Objections

Claims 1, 2 and 16 are objected to because of the following informalities: they contains multiple periods (".") in the body of the claim. Each claim begins with a capital letter and ends with a period. Periods may not be used elsewhere in the claim except for abbreviations. See *Fressola v. Manbeck*, 36 USPQ2nd 1211 (D.D.C. 1995). Appropriate correction is required.

- 4. The claims are objected to because the lines are crowded too closely together, making reading difficult. Substitute claims with lines one and one-half or double spaced on good quality paper are required. See 37 CFR 1.52(b).
- 5. Claim 12 and 14 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

# Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 3774

7. The claims are generally narrative and indefinite, failing to conform with current U.S. practice. They appear to be a literal translation into English from a foreign document and are replete with grammatical and idiomatic errors.

- 8. Independent claim 7 recites the limitation "the lining". There is insufficient antecedent basis for this limitation in the claim.
- 9. Claims 1 and 2 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite in that it fails to point out what is included or excluded by the claim language. This claim is an omnibus type claim. The use of "etc." and "not limited to" renders the scope undeterminable
- 10. Claim 19 provides for the use of ultrashort stents but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claim 19 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Art Unit: 3774

## Claim Rejections - 35 USC § 102

11. The following is a quotation of the appropriate paragraphs of 35U.S.C. 102 that form the basis for the rejections under this section made in thisOffice action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 12. Claims 1, 2 and 7-16 and 20-22 are rejected under 35 U.S.C. 102(b) as being anticipated as best understood (see 35 U.S.C. 112 rejections, above) by Strother 4,364,392.

Re claim 1 and 2, Strother discloses a balloon 11 catheter 15 that is inflatable, that can fill with liquid and block the flow of gas through a body lumen, comprised of any form of stent and any shape of stent and any material of stent, abstract.

Re claim 7, Strother discloses a means for injecting an inflation material into the balloon, 29.

Re claim 8 and 9, Strother teaches a check valve, 18, adapted to accept an inflating fluid or gas.

Re claim 10, as best understood, Strother teaches a valve formed by cutting a slit 29 which closes upon proper pressure application, col. 5, II. 1-10.

Re claim 11, see col. 3, II. 66.

Re claim 12, Strother teaches the device as disclosed above and claim 12 fails to further limit the claims.

Art Unit: 3774

Re claim 13, Strother teaches using a radiopaque marker col. 4 II. 30-35.

Re claim 14, Strother teaches the device as disclosed above and claim 14 fails to further limit the claims.

Re claim 15, Strother teaches a check valve that is of breakaway from, 18, as described in Strother, col. 5, II. 10-25.

Re claim 16, Strother teaches the balloon can be made of a semipermeable membrane, 71, porous polymer material plug 72.

Re claim 20, Strother teaches a balloon stent that has a narrowing lining which directs flow in a particular direction (towards the bulb end, 11).

Re claim 21, Strother teaches a balloon catheter fully capable of inflating together with a stent.

Re claim 22, Strother teaches a balloon catheter fully capable of fully occluding a lumen.

13. Claims 18 is rejected under 35 U.S.C. 102(b) as being anticipated <u>as best understood (see 35 U.S.C. 112 rejections, above</u>) by Rockey 4,641,653.

Rockey teaches a sleeve lining which is cylindrical, fig. 1, abstract.

# Claim Rejections - 35 USC § 103

- 14. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to

Art Unit: 3774

be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

15. Claims 17 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Strother 4,364,392.

16.

Re claim 17, Strother does not explicitly teach a gel material for 72.

However, gels are a well-known semi-permeable material used for similar applications. Therefore the office takes Official Notice of this common knowledge fact, that it would be obvious to one of ordinary skill in the art at the time of invention to use a gel as the porous polymer material 72.

Re claim 19, Strother does not explicitly teach the use of stents to support a narrowing lumen. However, supporting narrowing lumen with stents is so well-known in the art as to render it obvious to one of ordinary skill in the art.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JONATHAN R. STROUD whose telephone number is (571)270-3070. The examiner can normally be reached on Monday through Friday, 8:30 a.m. to 6 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Isabella David can be reached on (571)272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3774

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jonathan R Stroud/ Examiner, Art Unit 3774 /Thomas J Sweet/ Primary Examiner, Art Unit 3774